RAC 2.37% $1.65 race oncology ltd

FTO and link to AML and breast cancer treatment, page-37

  1. 11,249 Posts.
    lightbulb Created with Sketch. 29637
    One patent from memory filed ( not granted ) for CS1 ( aka Bisantrene) the other for CS2.

    The problem for COH is they didn’t file until either 2018 or 2019.

    RACE’s lead patent applied for in 2014 and granted in 2015.

    Notwithstanding being granted 3-4 years earlier, it’s the date of filing that matters most ( was 4-5 years earlier ).
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.